Sustainability & Climate

Trader Interactive and Roamly are embedding AI insurance into RV Trader, Cycle Trader, and Boatmart, making coverage instant and seamless for buyers.

Known for baked makeup, Laura Geller Beauty launches a cream palette, targeting women 40+ with a hydrating formula and a star-studded, age-positive campaign.

Daxor reports a transformative year with 45% revenue growth, a new FDA-cleared portable analyzer, and a full pivot to a high-growth medtech company.

An Atlanta clinic combines lasers, biologics, and AI to challenge traditional joint surgery. Can a new marketing push make it a national alternative?

After a transformational CEO retires, Byrna Technologies bets on new leadership to navigate the booming, competitive less-lethal defense market.

The neurohealth firm surpassed revenue estimates and hit positive cash flow, but a dynamic competitive landscape and CEO transition loom ahead of its earnings call.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

A new report reveals 87% of firms use AI in customer education, but a dangerous lack of strategy and governance threatens quality, security, and ROI.

Cognitiv's co-founders make ADWEEK's AI Power 50, a nod to their early bet on deep learning that is now reshaping advertising and beyond.

A new poll shows 81% of South Carolinians back energy choice for industry, but critics fear it could leave homeowners paying more for power.

A new five-year pact gives ISC employees raises to combat inflation while ensuring long-term stability for Saskatchewan’s critical public record services.

A new survey reveals a silent public health crisis as millions of Canadians face chronic sleep loss, with many admitting to driving while dangerously tired.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.

Axxess's upcoming conference tackles AI's role in home health, unveils a new leadership certification, and honors an industry titan. Here's what it means.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

Esperion's $75M+ deal for Corstasis and its novel nasal diuretic, Enbumyst, targets a $4B market and a new era of at-home edema management.

At ECR 2026, Subtle Medical showcases AI that boosts existing scanners, expands into CT, and promises faster, clearer diagnostics for patients.

Greenwich LifeSciences' Phase III trial for its GLSI-100 immunotherapy is enrolling patients faster than ever, with early data echoing past success.

Norsk Hydro plans to close its Lucé, France extrusion plant, impacting 80 jobs, as part of a wider strategy that has targeted six plants across Europe.